Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Non-Hodgkin 7Lymphoma, B-Cell 5Lymphoma 3Recurrence 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Hodgkin Disease 2Burkitt Lymphoma 2Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 18fludarabine phosphate 12pembrolizumab 11Nivolumab 11Brentuximab Vedotin 11Mycophenolic Acid 10Doxorubicin 10fludarabine 9Dacarbazine 9Whole-Body Irradiation 8Etoposide 8Vinblastine 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Filgrastim 7Cyclosporine 7Granulocyte Colony-Stimulating Factor 6Sirolimus 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Gemcitabine 5Busulfan 5Tacrolimus 4pegfilgrastim 3Vinorelbine 3Stem Cell Transplantation 3Rituximab 3Radiation 3Prednisone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hodgkin Disease × polatuzumab vedotin × 90 days × Clear all
NCT05615636 2026-05-20

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M.D. Anderson Cancer Center

Phase 2 Recruiting
36 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell

NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical College

Phase 1/2 Recruiting
20 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡